Edwards Lifesciences price target raised to $90-$91 from $82-$83 at Wells Fargo Wells Fargo increased its price target on Edwards after a federal court granted a preliminary injunction limiting the sale of a competing product, Medtronic's (MDT) CoreValve. The firm said the injunction was a "major surprise," and estimates that the injunction could increase Edwards EPS by 15c in 2014 and 34c in 2015. Wells keeps an Outperform rating on the stock.
News For EW From The Last 14 Days
Check below for free stories on EW the last two weeks.
Edwards Lifesciences price target raised to $120 from $95 at Piper Jaffray Piper Jaffray raised its price target for Edwards Lifesciences shares to $120 saying recent Transcatheter Aortic Valve Replacement market momentum is likely to continue. The firm keeps an Overweight rating on the stock.
Edwards Lifesciences price target raised to $114 from $103 at Canaccord Canaccord raised its price target on Edwards Lifesciences to $114 from $103 following positive updates on the SAPIEM franchise and on the heels of several positive trends and upside surprises across the businesses during the quarter. Canaccord maintains its Buy rating on the stock.